Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus

被引:10
|
作者
Peleg, Noam [1 ,2 ]
Schmilovitz-Weiss, Hemda [1 ,2 ]
Shamah, Steven [1 ,2 ]
Schwartz, Ariel [3 ]
Dotan, Iris [1 ,2 ]
Sapoznikov, Boris [1 ,2 ]
机构
[1] Rabin Med Ctr, Div Gastroenterol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Dept Pathol, Petah Tiqwa, Israel
关键词
DIAGNOSIS; MANAGEMENT; CANCER; GUIDELINES; DYSPLASIA; SURVIVAL;
D O I
10.1055/a-1292-8747
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Patient's with Barrett's esophagus (BE) are at risk of progression to esophageal adenocarcinoma (EAC). Neutrophil to lymphocyte ratio (NLR) was found to be a predictor of poor prognosis in patients with EAC; however, its performance in premalignant esophageal lesions is vague. We aimed to evaluate the utility of NLR as a predictor of histologic progression in patients with BE. Methods A prospective cohort of patients with proven BE in a tertiary referral center was retrospectively analyzed. All biopsies were reviewed by an expert gastrointestinal pathologist. The discriminatory capacity of NLR was evaluated by area under the receiver operating characteristic (AUC) curve analysis and Cox regression analysis. Results 324 patients (mean age 62.3 years, 241 [74.4%] males) were included in the final analysis. Overall, 13 patients demonstrated histologic progression to neoplasia over a mean follow-up of 3.7 years (progression risk 1.0% per year). The AUC of NLR for progression to high grade dysplasia (HGD) or EAC was 0.88 (95% confidence interval [CI] 0.83-0.96), and baseline NLR was associated with a 3-fold increase of progression to HGD and EAC during follow-up (hazard ratio [HR] 3.2, 95%CI 1.5-5.8; P <0.001). Notably, in a subgroup analysis of patients with nondysplastic BE (NDBE) at presentation, NLR was also a risk factor for histologic progression (HR 2.4, 95%CI 1.7-3.4; P <0.001). Conclusion NLR predicted histologic progression in patients with BE. Patients with NDBE and NLR above 2.4 can be considered for specific surveillance programs with shorter intervals between sessions.
引用
收藏
页码:774 / 781
页数:8
相关论文
共 50 条
  • [1] Risk factors for neoplastic progression in Barrett's esophagus
    Wiseman, Elizabeth F.
    Ang, Yeng S.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (32) : 3672 - 3683
  • [2] Risk factors for neoplastic progression in Barrett's esophagus
    Elizabeth F Wiseman
    Yeng S Ang
    World Journal of Gastroenterology, 2011, 17 (32) : 3672 - 3683
  • [3] NEUTROPHIL-TO-LYMPHOCYTE RATIO PREDICTS PROGRESSION TO HIGH GRADE DYSPLASIA AND ADENOCARCINOMA IN PATIENTS WITH BARRETT'S ESOPHAGUS
    Peleg, Noam
    Schmilovitz-Weiss, Hemda
    Shamah, Steven
    Dotan, Iris
    Sapoznikov, Boris
    GASTROENTEROLOGY, 2020, 158 (06) : S305 - S305
  • [4] Neoplastic progression in Barrett's esophagus
    Barrett, MT
    Sanchez, CA
    Galipeau, PC
    Neshat, K
    Cowan, DS
    Levine, DS
    Reid, BJ
    GENOMIC INSTABILITY AND IMMORTALITY IN CANCER, 1997, 8 : 195 - 214
  • [5] Higher risk of neoplastic progression of Barrett's esophagus in patients with systemic sclerosis
    Anilkumar, Mythri
    Alkhayyat, Motasem
    Grewal, Udhayvir S.
    Sanaka, Madhusudhan R.
    Thota, Prashanthi N.
    GASTROENTEROLOGY REPORT, 2021, 9 (06): : 595 - 596
  • [6] Segment length and risk for neoplastic progression in patients with Barrett esophagus
    El-Serag, HB
    ANNALS OF INTERNAL MEDICINE, 2000, 133 (09) : 747 - 748
  • [7] Proton Pump Inhibitors Reduce the Risk of Neoplastic Progression in Patients With Barrett's Esophagus
    Kastelein, Florine
    Spaander, Manon C. W.
    Steyerberg, Ewout W.
    Biermann, Katharina
    Valkhoff, Vera E.
    Kuipers, Ernst J.
    Bruno, Marco J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (04) : 382 - 388
  • [8] Barrett’s Esophagus: Model of Neoplastic Progression
    Stig Ramel
    World Journal of Surgery, 2003, 27 : 1009 - 1013
  • [9] Barrett's esophagus: Model of neoplastic progression
    Ramel, S
    WORLD JOURNAL OF SURGERY, 2003, 27 (09) : 1009 - 1013
  • [10] Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus
    Rudolph, RE
    Vaughan, TL
    Storer, BE
    Haggitt, RC
    Rabinovitch, PS
    Levine, DS
    Reid, BJ
    ANNALS OF INTERNAL MEDICINE, 2000, 132 (08) : 612 - +